Management of Myocardial Infarction: Emerging Paradigms for the Future

Vandan D Upadhyaya1, Christopher Wong2, Ramzan M Zakir2

  • 1Hackensack Meridian Health -Jersey Shore University Medical Center, Neptune City, New Jersey, US.

Insights

Reducing heart attack size may prevent heart failure. Left ventricular unloading strategies, including microaxial flow devices, show promise in improving outcomes for acute myocardial infarction patients.

Area of Science:

  • Cardiology
  • Cardiovascular Research
  • Medical Interventions

Background:

  • Acute ST-segment elevation myocardial infarctions (STEMI) management has advanced, yet heart failure prevalence remains high.
  • Reducing infarct size is a key strategy to improve outcomes after acute coronary syndromes.
  • Left ventricular (LV) unloading has emerged as a potential mechanism for limiting infarct size.

Purpose of the Study:

  • To review clinical data on infarct size reduction in acute myocardial infarction.
  • To highlight ongoing clinical trials exploring new therapeutic approaches for myocardial infarction management.
  • To assess the role of LV unloading in improving outcomes for acute myocardial infarction patients.

Main Methods:

  • Review of clinical trial data focusing on infarct size reduction.
  • Analysis of contemporary use of microaxial flow devices for LV unloading.
  • Examination of evidence for improved mortality in acute myocardial infarction with cardiogenic shock.

Main Results:

  • Emerging paradigms focusing on infarct size reduction show promise in decreasing heart failure incidence post-acute coronary syndromes.
  • LV unloading, particularly with microaxial flow devices, has shown potential for improved mortality in acute myocardial infarction complicated by cardiogenic shock.
  • Clinical data demonstrate evidence of infarct size reduction as a therapeutic goal.

Conclusions:

  • Limiting infarct size is a critical therapeutic target for managing acute myocardial infarction and preventing heart failure.
  • Left ventricular unloading represents a promising strategy with potential to improve mortality in severe acute myocardial infarction.
  • Ongoing clinical trials are exploring novel approaches to infarct size reduction, offering new hope for patients.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
464